ESTEVE, one of the leading pharmaceutical groups in Spain, has entrusted OYTEC with the digitalisation of its plant operations. As part of its digitalisation strategy, its main objective is to eliminate paper from the plant floor as far as possible and achieve a “Paperless” manufacturing environment. To this end, all paper batch records (MBR) will be replaced with Electronic Batch Records (EBR), all automatically integrated with the SAP ERP.
The project covers the digitalisation of four of its production sites: the Banyeres del Penedès and Celrà plants in Catalonia, the EHP plant in China and the Sintenovo plant in Mexico. The project has been contracted on a “Turnkey” and Global Roll-Out basis, including full validation of the EBR platform at all four plants.
The main objectives that have led ESTEVE to undertake this digitalisation project are focused on minimising the inefficiencies of paper-based working and mitigating potential errors arising from manual operations. Together with new regulatory requirements, these factors mean that far more time and resources are needed to secure manufacturing processes.
- Reductions of up to around 98% in Batch Record deviations/investigations.
- Batch Record review times reduced by more than 75% thanks to Real-Time Review by Exception.
- Data entry times reduced by around 75%.
It is possible to secure the audit trail and improve compliance, hand in hand with Operational Excellence, by implementing the EBR Electronic Batch Record.
Fast & Furious eBR Implementation
YES, that's right, a Fast & Furious eBR Implementation is possible. It is no longer a utopia to carry out an Electronic Batch Record implementation in a fast and massive way for any manufacturing plant. Regardless of the manufacturing area: bulk, weighing, or...
EMA and FDA: The 10 Principles of Pharmaceutical AI
The European Union and the United States published the Guiding Principles for Good AI Practices in Drug Development on January 14, 2026, as part of a strategic effort to harmonize regulatory criteria. The EMA-FDA collaborative work initiative has the mission of...
The FDA and Pharmaceutical AI: Key Points from the 2025 Draft on Model Credibility
The FDA positions credibility as an indispensable condition for utilising AI in pharmaceutical regulatory decision-making, within a risk-proportionate framework that demands traceability, transparency and validation throughout the entire model lifecycle. This approach...




